Cancer treatment has made remarkable advances, but some targets remain difficult to address, especially for aggressive and poorly treatable forms like childhood gliomas. Revolver Therapeutics, a spin-out from the University of Bath, is taking a bold step in tackling these difficult to drug targets. Using its proprietary Transcription Block Survival (TBS) assay platform, Revolver is developing groundbreaking peptide inhibitors that target transcription factors – master regulators of gene activity and critical players in cancer progression. With its recent seed funding, Revolver is progressing therapies for childhood gliomas and exploring broader applications for adult cancers.
Revolver’s proprietary TBS platform identifies cell-penetrating peptides that inhibit transcription factors. Transcription factors control gene activity, and their deregulation is often central to cancer. Unlike traditional therapies, Revolver’s peptides bypass the hurdles faced by small molecules and antibodies, offering a new path to effective cancer treatments.
The platform is built on cutting-edge engineering biology, developed by Professor Jody Mason at the University of Bath. Revolver’s inhibitors not only achieve anti-tumor effects but also solve the cellular penetration challenges that have long limited the delivery of biologics.
investment to kickstart Revolver's seed round
total grant funding secured through the Innovate UK Transforming Cancer Therapeutics programme
of first-in-class peptide therapeutics targeting transcription factors.
"Revolver Therapeutics is pioneering an exciting new approach to cancer treatment by targeting transcription factors—proteins that have been tough to tackle in cancer research until now. Their novel platform produces first-in-class, cell-penetrating peptides with an excellent product profile, and with this investment, they are now advancing their first therapeutic assets. We’re proud to support Revolver's team as they bring this innovative science closer to helping patients facing challenging cancers."
UKI2S is proud to support Revolver Therapeutics in its mission to transform cancer care. By providing seed investment, strategic guidance, and connections to co-investors, UKI2S is helping Revolver bring life-changing therapeutics closer to reality. This funding enables the development of Revolver’s peptide-based inhibitors while de-risking its platform and positioning the company for future growth. The collaboration with renowned partners like The Institute of Cancer Research solidifies Revolver’s potential to make a profound impact in oncology.
© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, t/a Midven, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.
